Monteverde & Associates PC has launched investigations into the proposed mergers of Corebridge Financial, RE/MAX Holdings, Selectis Health, and Apogee Therapeutics to determine if the boards of these companies adequately acted in the best interests of shareholders. The law firm is examining potential breaches of fiduciary duty and other legal violations related to the transaction terms and the processes used to secure shareholder approval.

The investigations cover four distinct transactions with varying deal structures and shareholder vote deadlines. Corebridge Financial is merging with Equitable Holdings, while RE/MAX Holdings is being sold to The Real Brokerage Inc. Selectis Health is selling to Black Pearl Equities II, and Apogee Therapeutics is being acquired by AbbVie Inc. The firm is reviewing whether the consideration offered to shareholders is fair and if all material information was disclosed prior to the votes.

Transaction Details and Deadlines

The following table summarizes the key details of the mergers under investigation, including the proposed consideration and critical dates for shareholders.

Shareholder Actions

Monteverde & Associates PC advises shareholders who own stock in these companies to contact the firm to discuss their rights and potential legal remedies. The firm emphasizes that there is no cost or obligation for the consultation. Shareholders must act promptly given the approaching deadlines for votes and tender offers.

Juan Monteverde, the lead attorney at Monteverde & Associates PC, stated that the firm is focused on recovering losses for shareholders and ensuring that corporate boards adhere to their fiduciary duties during merger negotiations. The firm is headquartered at the Empire State Building in New York City and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

Barclays analyst Alex Scott has maintained an Overweight rating on Corebridge Financial, raising the price target to $33 from the previous $30. The adjustment signals a positive outlook on the company's stock performance.

Rating and Price Target Update

The analyst's decision to retain the Overweight rating accompanies a revised price target. The new target of $33 represents an increase from the prior $30, indicating an expected upside in the stock's value.

The revised target underscores the analyst's confidence in Corebridge Financial's fundamentals and market position.